Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. (Nasdaq: KROS) on June 23, 2026. The report discloses the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Anne Prener, M.D., Ph.D., as a director, effective July 1, 2026. Dr. Prener was appointed as a Class III director with a term expiring at the 2029 annual meeting of stockholders. No other material changes to the Company's operations or financial status are disclosed in this report.
Guidance, Outlook, and Compensation Details
There is no forward-looking guidance or management commentary regarding business outlook in this filing. The report details the following compensatory arrangements for Dr. Prener:
- Initial Equity Grants: An initial stock option grant and an initial restricted stock unit (RSU) award, each with a grant date fair value of $150,000. Both grants vest over a three-year period in equal quarterly installments, subject to continuous service, with full acceleration upon a Change in Control.
- Annual Equity Grants: Eligibility for annual option and RSU grants, each with a grant date fair value of $75,000, to be granted at the annual meeting of stockholders.
- Cash Retainer: An annual cash retainer of $41,500 for Board service.
- Indemnification: The Company will enter into a standard indemnification agreement with Dr. Prener.
Investor Verification Checklist
- Verify the effective date of Dr. Prener's appointment (July 1, 2026) and her Class III director term expiration (2029).
- Confirm the total initial equity compensation value ($300,000 combined fair value for options and RSUs) and the vesting schedule.
- Review the Company's 2020 Equity Incentive Plan to understand the 0.075% outstanding share cap on initial grants.
- Check for any potential conflicts of interest, though the filing states none exist under Item 404(a) of Regulation S-K.